Active Ingredient History
Prexasertib (LY2606368) is a small molecule checkpoint kinase inhibitor, mainly active against CHEK1, with minor activity against CHEK2. This causes induction of DNA double-strand breaks resulting in apoptosis. It was developed by Eli Lilly but the company announced in 2019 it was dropping prexasertib from active development, although clinical trials continue. Research continues into the efficacy of prexasertib in treatment of acute myeloid leukemia, myelodysplastic syndrome, rhabdomyosarcoma, and medulloblastoma. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Brain Neoplasms (Phase 1)
Breast Neoplasms (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 1)
Carcinoma, Squamous Cell (Phase 1)
Carcinoma, Transitional Cell (Phase 1/Phase 2)
Central Nervous System Neoplasms (Phase 1)
Colorectal Neoplasms (Phase 1)
Desmoplastic Small Round Cell Tumor (Phase 1/Phase 2)
Endometrial Neoplasms (Phase 1/Phase 2)
Head and Neck Neoplasms (Phase 1)
Leukemia, Myeloid, Acute (Phase 1)
Leukemia, Myelomonocytic, Chronic (Phase 1)
Lung Neoplasms (Phase 1)
Medulloblastoma (Phase 1)
Myelodysplastic Syndromes (Phase 1)
Neoplasm Metastasis (Phase 1)
Neoplasms (Phase 2)
Ovarian Neoplasms (Phase 2)
Prostatic Neoplasms (Phase 2)
Rectal Neoplasms (Phase 1)
Rhabdomyosarcoma (Phase 1/Phase 2)
Small Cell Lung Carcinoma (Phase 2)
Squamous Cell Carcinoma of Head and Neck (Phase 1)
Triple Negative Breast Neoplasms (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue